Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41571-023-00812-8 | DOI Listing |
Adv Ther
May 2021
EMD Serono Inc., Rockland, MA, USA; an affiliate of Merck KGaA, Darmstadt, Germany.
Introduction: Substantial unmet needs exist among patients with metastatic renal cell carcinoma (mRCC). This retrospective study evaluated treatment patterns as well as clinical and economic outcomes associated with first-line monotherapy among patients with mRCC in the USA.
Methods: Newly diagnosed patients with mRCC initiating at least one first-line therapy (1L) from 1 October 2013 to 31 March 2018 (index date = 1L start date) were identified from the US Veterans Health Administration database.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!